LEVERKUSEN, Germany, Oct. 22 [Category: BizPharmaceuticals] -- Bayer Group, a pharmaceutical and life sciences company, posted the following news release:

* * *

Finerenone showed consistent effects in reduction of UPCR, UACR and kidney function decline versus placebo in diverse patient populations with chronic kidney disease without diabetes

*

Berlin, October 22, 2026 - Bayer today announced results from two subgroup analyses from the Phase III . . .

Click here for more information about our products